依达拉奉联合氯吡格雷治疗急性脑梗死的临床治疗效果研究

Clinical Efficacy of Edaravone Combined with Clopidogrel in the Treatment of Acute Cerebral Infarction

目的探讨和分析依达拉奉联合氯吡格雷在治疗急性脑梗死的临床治疗效果。方法方便选取该院收治的自2017年1月-2018年12月脑梗死患者100例,按随机原则分成对照组和观察组,各50例,对于对照组患者,均服用氯吡格雷,对于实验组患者,选择依达拉奉配合氯吡格雷的策略该2组都连续给药14 d,然后对比两组疗效、NIHSS评分、 ADL评分和不良反应发生率。结果实验组总有效率达到86.00%(43/50),显著优于对照组66.00%(33/50),该两组总有效率对比差异有统计学意义(χ^2=9.160 9,P<0.05);治疗后实验组7 d与14 d、以及21 d的NIHSS评分依次是(75.16±6.01)分、(81.02±7.15)分、(86.09±6.13)分,均显著优于对照组;实验组患者14 d以及21 d的ADL评分依次是(69.36±5.17)分、(81.63±6.19)分,均优于对照组,两组治疗后14 d、以及21 d的该指标对比差异有统计学意义(t=9.601 5、7.109 1,P<0.05);实验组和对照组不良反应发生率分别为8%、10%,该两组不良反应率对比,差异无统计学意义(χ^2=1.034 1,P>0.05)。结论依达拉奉联合氯吡格雷被属于救治急性脑梗死的适合策略,不但可加快患者神经系统的恢复、以及促进预后,还不易引起明显的负面反应,使其日常生活能力得以增强,有极大的推广价值。

Objective To investigate and analyze the clinical effect of edaravone combined with clopidogrel in the treatment of acute cerebral infarction. Methods A total of 100 patients with cerebral infarction admitted to our hospital from January2017 to December 2018 were convenient selected and randomly divided into the control group and the observation group(50 cases each). The control group took clopidogrel, and the experimental group took the strategy of edaravone combined with clopidogrel for 14 consecutive days. The efficacy, NIHSS score, ADL score and adverse effects of the two groups were compared. Results The total effective rate of the experimental group was 86.00%(43/50), which was significantly better than that of the control group(66.00%(33/50)). There was significant difference between the two groups(χ^2=9.160 9, P<0.05). After treatment, the NIHSS scores of the experimental group on 7 d day, 14 d day and 21 d day were(75.16±6.01)points,(81.02±7.15)points,(86.09±6.13)points respectively, which were significantly better than those of the control group.The ADL scores of the experimental group on 14 d day and 21 d day were(69.36 ±5.17)points and(81.63 ±6.19)points respectively, which were superior to those of the control group. There were significant differences between the two groups(t=9.601 5, 7.109 1, P<0.05). The incidence of adverse reactions in the experimental group and the control group were 8% and10%, respectively, and there was no significant difference between the two groups(χ^2=1.034 1, P >0.05). Conclusion Edaravone combined with clopidogrel is a suitable strategy for the treatment of acute cerebral infarction. It can not only accelerate the recovery of patients’ nervous system, but also promote the prognosis. It reduces the probability of causing obvious negative reactions and enhance their daily living ability. It has great popularization value.